EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY

Giant cell arteritis (GCA), formerly known as Horton's disease, is among the most common diseases from a group of systemic vasculitides; its clinical significance is complemented with the potential involvement of the coronary arteries, aorta, and cranial arteries with development of ischemic op...

Full description

Bibliographic Details
Main Authors: T. V. Beketova, M. A. Ushakova, N. Yu. Nikishina, A. N. Khelkovskaya-Sergeeva, E. V. Nikolaeva, E. G. Sazhina, T. M. Novoselova, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2018-05-01
Series:Научно-практическая ревматология
Subjects:
giant cell arteritis
interleukin 6
tocilizumab
Online Access:https://rsp.mediar-press.net/rsp/article/view/2529

Similar Items

Similar Items